Barclays’s Orexigen Therapeutics, Inc. OREX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q1 | – | Sell |
-1,450
| Closed | -$3K | – | 7286 |
|
|
2016
Q4 | $3K | Hold |
1,450
| – | – | ﹤0.01% | 6316 |
|
|
2016
Q3 | $5K | Sell |
1,450
-1,530
| -51% | -$5.78K | ﹤0.01% | 6051 |
|
|
2016
Q2 | $13K | Buy |
+2,980
| New | +$13.5K | ﹤0.01% | 5466 |
|
|
2016
Q1 | – | Sell |
-4,540
| Closed | -$45K | – | 6893 |
|
|
2015
Q4 | $45K | Sell |
4,540
-8,350
| -65% | -$199K | ﹤0.01% | 4869 |
|
|
2015
Q3 | $258K | Buy |
12,890
+4,000
| +45% | +$137K | ﹤0.01% | 3945 |
|
|
2015
Q2 | $356K | Buy |
8,890
+1,310
| +17% | +$78.3K | ﹤0.01% | 3743 |
|
|
2015
Q1 | $531K | Sell |
7,580
-3,890
| -34% | -$241K | ﹤0.01% | 3572 |
|
|
2014
Q4 | $688K | Sell |
11,470
-1,080
| -9% | -$54.2K | ﹤0.01% | 3543 |
|
|
2014
Q3 | $502K | Buy |
12,550
+6,530
| +108% | +$351K | ﹤0.01% | 3951 |
|
|
2014
Q2 | $361K | Sell |
6,020
-3,420
| -36% | -$199K | ﹤0.01% | 4287 |
|
|
2014
Q1 | $566K | Sell |
9,440
-4,880
| -34% | -$330K | ﹤0.01% | 3835 |
|
|
2013
Q4 | $716K | Buy |
14,320
+3,250
| +29% | +$183K | ﹤0.01% | 3739 |
|
|
2013
Q3 | $664K | Buy |
11,070
+3,950
| +55% | +$268K | ﹤0.01% | 3796 |
|
|
2013
Q2 | $416K | Buy |
+7,120
| New | +$438K | ﹤0.01% | 4434 |
|
Other funds holding OREX
Barclays's OREX Position: Q2 2018 in Review
Barclays sold out of Orexigen Therapeutics, Inc. (OREX) in Q2 2018, closing a stake of 5 shares.
Barclays first reported a position in OREX in Q2 2013 and held it in 19 quarters. The position peaked at $1.07M in Q2 2014. 4 funds tracked by Wall St. Rank hold OREX as of Q2 2018.
- Barclays reported no remaining Orexigen Therapeutics, Inc. position as of Q2 2018 after selling out during the quarter.
- Barclays sold 5 Orexigen Therapeutics, Inc. shares in Q2 2018.
- Barclays first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 19 quarters.
- Barclays's Orexigen Therapeutics, Inc. position peaked at $1.07M in Q2 2014.
- 4 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q2 2018.
Based on Barclays's 13F filing for Q2 2018, filed 14 Aug 2018.